Pepsin-trypsin digested gliadin treatment in intestinal cells

Ane Olazagoitia-Garmendia

doi:10.1016/bs.mcb.2022.11.002

Pepsin-trypsin digested gliadin treatment in intestinal cells

Methods Cell Biol. 2023:179:1-11. doi: 10.1016/bs.mcb.2022.11.002. Epub 2022 Dec 16.

Author

Ane Olazagoitia-Garmendia¹

Affiliation

¹ University of the Basque Country, UPV/EHU, Leioa, Spain; Biocruces Bizkaia, Health Research Institute, Barakaldo, Spain. Electronic address: ane.olazagoitia@ehu.eus.

PMID: 37625867
DOI: 10.1016/bs.mcb.2022.11.002

Abstract

Celiac disease (CD) is an intestinal autoimmune disorder developed in genetically susceptible individuals upon gluten ingestion. Gliadin is known to be the most immunogenic gluten component, which can activate the host immune response represented by NFkB activation and release of proinflammatory cytokines as IL8. However, many aspects of the involvement of gliadin in CD pathophysiology is not well understood yet. Lack of a CD animal model increases difficulty elucidating key steps in CD development, what increases the importance of in vitro experiments. Here we present a protocol for in vitro pepsin-trypsin digested gliadin (PTG) treatment for long term studies in HCT116 intestinal cell line.

Keywords: HCT116; IL8; In vitro model; NFkB; gliadin; inflammation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Gliadin*
Glutens
Intestines
Pepsin A*
Trypsin

Substances

Gliadin
Pepsin A
Trypsin
Glutens